Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy - Novartis

Novartis Advances Immunology And Oncology Plans As Valuation Gap Persists - Yahoo Finance

Will Novartis AG Depositary Receipt stock remain a Wall Street favorite - Forecast Cut & Proven Capital Preservation Methods - Naître et grandir

Novartis receives positive CHMP opinion for remibrutinib in chronic spontaneous urticaria (CSU) - Novartis

Novartis (NVS) Shareholders Approve Key Resolutions at Annual Me - GuruFocus

Novartis, Nucor partner US Forged Rings and others expand domestic investments - Manufacturing Dive

Novartis AG Approves Dividend for 2025, Payable from March 12, 2026 - marketscreener.com

Aplastic Anemia Market Expected to Experience Major Growth by 2034, According to DelveInsight | Pfizer, Regeneron Pharma, Gamida-Cell, Kyowa Kirin, Novartis, Jiangsu HengRui - StreetInsider

Charles Swanton, M.B.Ph.D. - Novartis

Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2026 Annual General Meeting - Novartis

Foresight Global Investors Inc. Increases Stake in Novartis AG $NVS - MarketBeat

KVS, NVS tier 2 admit card 2026 expected to be released soon at kvsangathan.nic.in: Check details here - MSN

Novartis to Build New Radioligand Therapy Site in Denton, Texas - Contract Pharma

Aerospace Medicine Market is Going to Boom | Major Giants Pfizer, Novartis, Bayer - openPR.com

KVS, NVS Tier 2 admit card 2026 expected soon, exams to be held from March 27 - India Today

Skeletal Dysplasia Market - Global Forecast 2026-2032: $5.37 Bn Opportunities Driven by Advancing Diagnostic Precision, Integrated Therapies, Evidence Generation, and Equitable Access

Cytokines Market Global Forecast 2026-2032: Precise Treatments, Strategic Partnerships, and Supply Chain Resilience Fueling the $95+ Billion Market

KVS NVS Tier 2 Admit Card 2026, Phase 2 Call Letter & City Intimation - Career Power

Reckitt refreshes board with senior hires from Novartis and Smith+Nephew - TipRanks

American Century Companies Inc. Lowers Position in Novartis AG $NVS - MarketBeat

KVS and NVS Tier 2 Exam Date 2026 Out, Check Schedule And Notice Here - Physics Wallah

Novartis settles with Henrietta Lacks estate over use of her ‘stolen’ cells to advance medicine - New York Amsterdam News

Pre-Market Most Active: Novartis (NOVN.SW) on SIX at CHF127.68: watch short-term upside - Meyka

Novartis to build new radioligand therapy site in Denton, Texas, delivering more next‑generation treatments to patients - Novartis

Novartis Settles With Henrietta Lacks’ Estate - The San Diego Voice & Viewpoint

Henrietta Lacks Family Secures Settlement With Novartis Over HeLa Cells - The Washington Informer

Novartis And Henrietta Lacks’ Family Reach A Settlement - Forbes

Dimensional Fund Advisors LP Has $1.13 Billion Stake in Novartis AG $NVS - MarketBeat

Atrium Therapeutics born from Novartis-Avidity deal to pioneer RNA therapies - BioXconomy

Novartis Updates Highlight BTKi Progress Radioligand Expansion And Valuation Debate - simplywall.st

Why Novartis Outshines Amarin as a Safe Bet in a Volatile Market - NAI500

Are Novartis leaders really this bad?

Novartis' Rhapsido Gets Positive CHMP Opinion for Urticaria in EU - The Globe and Mail

Henrietta Lacks’ Estate Reaches Confidential Settlement With Novartis - bet.com

Novartis AG (NVS) Stock Price Down 3.43% on Mar 3 - GuruFocus

2026 ASCO GU Update

Teachers Retirement System of The State of Kentucky Boosts Holdings in Novartis AG $NVS - MarketBeat

Stanislav Kondrashov on Swiss Re, Rheinmetall and Novartis in the Era of Strategic Protection - vocal.media

Sarayevka, NVS, RU UV Index Report - The Weather Network

AI in Pharma Manufacturing Market Research 2026-2040: Pfizer, Moderna, Novartis, Merck, and Sanofi are Integrating AI Into Their Operations As the Sector Evolves Towards Pharma 4.0 - Yahoo Finance UK

Transition into industry MD,PhD

Novartis plans radioligand therapy manufacturing site in Texas - DOTmed

Commit fully to the role you’re in now, and your career may thank you later: Novartis CEO Vas Narasimhan - CNBC

Novartis Stock Today, March 03: Pullback From High as Holds Lead - Meyka

CHF129.96 NOVN.SW Novartis AG (SIX) 03 Mar 2026 pre-market: most active, key outlook - Meyka

Novartis Settles with Henrietta Lacks’ Estate Over Profits From Her ‘Stolen’ Cells - EURweb

Novartis AG (NVS) Stock Analysis: Evaluating a Healthcare Leader with a Strong Dividend Yield and Robust Cash Flow - DirectorsTalk Interviews

Trading Systems Reacting to (NVS) Volatility - Stock Traders Daily

Novartis settles with Henrietta Lacks' estate over use of her cancer cells to advance medicine - PBS

Assessing Novartis (SWX:NOVN) Valuation After Strong Recent Share Price Momentum - simplywall.st

Novartis Forges Ahead With Rhapsido For Food Allergy - Citeline News & Insights

“Novartis has settled a lawsuit by the estate of Henrietta L... - Kottke.org

Novartis plans $280M facility in Denton to produce ‘next-generation’ cancer treatments - Denton Record-Chronicle

Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy - marketscreener.com

What's Driving the Market Sentiment Around Novartis AG? - Benzinga

KVS NVS Result 2026 Out, Download Tier 1 Score Card & Result - Career Power

Novartis AG $NVS Shares Acquired by Fisher Asset Management LLC - MarketBeat

KVS NVS Tier II Exam Date 2026: Check Teaching and Non-Teaching Exam Schedule - Jagran Josh

New biotech Atrium born out of Novartis/Avidity marriage - pharmaphorum

Headlines from across the state: Henrietta Lacks’ family settles suit with Novartis over use of her cells; more ... - Cardinal News

Novartis’ Rhapsido shows promise in Phase 2 food allergy data - Endpoints News

KVS NVS Tier 2 exam from 27 to 31 March 2026, download detailed syllabus and Tier 1 result here - The Times of India

KVS, NVS Tier-I Result 2026 Out; Tier-II Full Exam Schedule and Syllabus Released - Telegraph India

ISRO Cites Connector Failure in NVS-02 Loss, But Questions Linger - Orbital Today

Novartis AG (NYSE:NVS) Short Interest Update - MarketBeat

KVS NVS Cut Off 2026, Check Expected & Previous Year Cut-Off Marks - Career Power